Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 60Stomach Neoplasms 27Rectal Neoplasms 20Colonic Neoplasms 19Small Cell Lung Carcinoma 12Pancreatic Neoplasms 11Neoplasm Metastasis 10Locally Advanced Rectal Cancer 5Colorectal Cancer Metastatic 5Esophageal Squamous Cell Carcinoma 4Esophageal Neoplasms 4Biliary Tract Neoplasms 4Recurrence 3Liver Neoplasms 3Glioblastoma 3Cholangiocarcinoma 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Solid Tumors 2Sarcoma 2Lung Neoplasms 2Glioma 2Gastrointestinal Neoplasms 2Gallbladder Neoplasms 2Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction 2Advanced Colorectal Cancer 2mCRC 1Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocytopenia 1Second Line Treatment of Gastric Cancer 1

Interventions

S 1 (combination) 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Cetuximab 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × mCRC × Irinotecan × Clear all
NCT03567629 2018-06-26

Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer

Peking University

Phase 2 Unknown
130 enrolled

mCRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡